Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Instagram Outage Disrupts Thousands of U.S. Users 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
ST. HELIER, Jersey, Sept. 30, 2016 -- In a press release issued under the same headline earlier today by Novocure, Ltd. (Nasdaq:NVCR), please note that the first paragraph should say "the three and nine months ended Sept. 30, 2016" rather than "the three and six months ended Sept. 30, 2016" as previously stated. The corrected release follows:
Novocure to Report Third Quarter 2016 Financial Results
Novocure (NASDAQ:NVCR) announced today that it will report financial results for the third quarter 2016 on Wednesday, Nov. 2, 2016, before the open of U.S.-based financial markets. Novocure management will host a conference call and webcast to discuss its financial results for the three and nine months ended Sept. 30, 2016, at 8 a.m. EDT on Wednesday, Nov. 2, 2016.
The conference call can be accessed by dialing 877-726-5929 for domestic callers and 530-379-4648 for international callers, using the conference ID 76871474. The webcast can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investors, and will be available for replay for at least 14 days following the call.
About Novocure
Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
Media and Investor Contact: Ashley Cordova 212-767-7558 [email protected]
